Top Medical News
MACE risk higher with tofacitinib vs TNFi in patients with RA, ASCVD
5 days ago
In the treatment of patients with rheumatoid arthritis (RA) and atherosclerotic cardiovascular disease (ASCVD), the use of tofacitinib confers an increased risk of major adverse cardiovascular events (MACE) than tumour necrosis factor inhibitors (TNFi), according to a post hoc analysis of ORAL Surveillance.
Pirfenidone may benefit RA-ILD patients
Audrey Abella, 20 Sep 2022
In the phase II TRAIL1 trial, oral pirfenidone slowed the rate of decline in lung function in individuals with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Female gout patients at higher risk of SARS-CoV-2 infection, severe sequelae
18 Sep 2022
Despite being vaccinated against COVID-19, women with gout have an excess risk of developing SARS-CoV-2 infection as well as severe sequelae from it, according to a study.
Product Highlight - Idacio
13 Sep 2022
Adalimumab soln for inj 40 mg/0.8 mL
Patients upset by frequent side effects of RA drugs
Stephen Padilla, 12 Sep 2022
Symptomatic adverse events (AEs) are common and troublesome for many patients with rheumatoid arthritis (RA) who are taking medications for their condition, results of an exploratory study have shown.
Sural nerve biopsy improves diagnosis of vasculitis
11 Sep 2022
Patients who undergo sural nerve biopsy (SNB) have a better diagnostic yield for vasculitis, results of a study have shown.
Dactylitis predicts more severe joint damage, higher disease activity in axPsA
10 Sep 2022
The presence of dactylitis in patients with axial psoriatic arthritis (axPsA) may result in higher disease activity and more severe joint damage compared to those without, reports a study.
Special Reports
Product Highlight - Idacio
13 Sep 2022
Adalimumab soln for inj 40 mg/0.8 mL
Product Highlight - Locoa
01 Dec 2021
Esflurbiprofen 40 mg transdermal patch
Product Highlight - Rinvoq
01 Dec 2021
Upadacitinib 15 mg XR-FC tab
Product Highlight - Evenity
01 Dec 2021
Romosozumab 105 mg/1.17 mL soln for inj
Conference Reports
Baricitinib delays, lowers frequency of flares in JIA
Roshini Claire Anthony, 23 Jun 2022

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Roshini Claire Anthony, 20 Jun 2022

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

Bimekizumab shows promise across the spectrum of axial spondyloarthritis
Elaine Soliven, 18 Jun 2022
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
Antihistamines potentially beneficial for knee OA
Audrey Abella, 17 Jun 2022
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
JAK inhibition with upadacitinib works well in nr-axSpA
Elvira Manzano, 16 Jun 2022
Treatment with upadacitinib improves disease activity, pain, function, and quality of life (QoL) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a study touted as the first to evaluate a Janus kinase (JAK) inhibitor for this condition.
Sarilumab shows potential for relapsing polymyalgia rheumatica
Audrey Abella, 15 Jun 2022
The monoclonal antibody sarilumab demonstrated significant efficacy in individuals with relapsing polymyalgia rheumatica (PMR), findings from the phase III SAPHYR trial have shown.
Vitamin D, fish oil: protective against autoimmune diseases?
Audrey Abella, 13 Jun 2022
In the postintervention results of the VITAL* trial, vitamin D and marine omega-3 fatty acids (n-3 FAs) continued to demonstrate a protective effect against autoimmune diseases in older adults.